The United Kingdom and the United States have secured a significant trade agreement that will maintain zero tariffs on UK medicine exports being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase spending on pharmaceuticals through the public health system. This commitment ensures that import taxes on these crucial products will remain at nothing for a duration of 36 months.
This agreement comes after previous warnings to hike duties on patented pharmaceutical products, with potential rates mentioned as high as 100%.
"This deal with the United Kingdom bolsters the global environment for cutting-edge drugs and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," an announcement noted.
Economic Significance
Pharmaceuticals represent one of the Britain's most significant export categories to the US, which is clearly the primary buyer for major British pharmaceutical firms.
Trade data indicate that in the 12 months leading up to the third quarter, the UK sold medicines valued at £11.1bn to the US. This amount accounted for a significant portion of total UK exports in that period.
"This guarantee safeguards employment, increases capital expenditure and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Specific NHS Changes
The deal includes several specific commitments from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to increase total NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum manufacturers must pay back to the NHS to prevent overspending will be limited at fifteen percent. Previously, refunds topped twenty percent.
Recent Tensions
The deal comes amid a long-running row between the sector and the UK government over drug pricing and approval rates.
This friction were heightened by assertions that US patients were charged several times more for the equivalent treatments than people in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS needed to spend more on drugs, noting that its spending on drugs had decreased as a percentage of its total funding over the previous ten-year period.
